| Browse All

Longeveron Inc. (LGVN)

Healthcare | Biotechnology | Miami, United States | NasdaqCM
1.10 USD 0.00 (-0.452%) ⇩ (April 17, 2026, 3:55 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:30 p.m. EDT

The stock has shown some recent volatility, with a price range between $0.89 and $1.16 over the last 14 days. However, the negative forward P/E and negative EPS suggest poor financial health and potential earnings issues. The stock's current price is near its 52-week low, indicating possible undervaluation. The negative beta and negative return on assets suggest it is a high-risk investment. While there are some positive news headlines, such as the $30 million private placement financing and a patent grant, the lack of consistent dividend payouts and the overall negative financial metrics make it a high-risk short-term play. Long-term investors should be cautious given the lack of sustainable growth and the negative fundamentals.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.289984
MSTL0.296909
AutoTheta0.378592
AutoARIMA0.577503

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 40%
H-stat 109.88
Ljung-Box p 0.000
Jarque-Bera p 0.049
Excess Kurtosis -1.57
Attribute Value
Sector Healthcare
Debt to Equity Ratio 14.52
Revenue per Share 0.068
Market Cap 32,062,846
Forward P/E -0.72
Beta -0.19
Previous Name Longeveron LLC
Website https://longeveron.com

Info Dump

Attribute Value
52 Week Change -0.2763158
Address1 Life Science & Technology Park
Address2 Suite 520 1951 NW 7th Avenue
All Time High 450.0
All Time Low 0.475
Ask 1.15
Ask Size 1
Average Daily Volume10 Day 1,037,810
Average Daily Volume3 Month 5,635,919
Average Volume 5,635,919
Average Volume10Days 1,037,810
Beta -0.19
Bid 1.04
Bid Size 1
Book Value 0.247
City Miami
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.095
Current Ratio 1.334
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.14
Day Low 1.0801
Debt To Equity 14.52
Display Name Longeveron
Earnings Call Timestamp End 1,773,779,400
Earnings Call Timestamp Start 1,773,779,400
Earnings Timestamp 1,773,777,600
Earnings Timestamp End 1,778,184,000
Earnings Timestamp Start 1,778,184,000
Ebitda -22,061,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.986
Enterprise To Revenue 18.146
Enterprise Value 21,757,530
Eps Forward -1.53
Eps Trailing Twelve Months -1.29
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.79736
Fifty Day Average Change 0.29764003
Fifty Day Average Change Percent 0.37328187
Fifty Two Week Change Percent -27.63158
Fifty Two Week High 1.83
Fifty Two Week High Change -0.735
Fifty Two Week High Change Percent -0.40163934
Fifty Two Week Low 0.475
Fifty Two Week Low Change 0.62
Fifty Two Week Low Change Percent 1.3052632
Fifty Two Week Range 0.475 - 1.83
Financial Currency USD
First Trade Date Milliseconds 1,613,140,200,000
Float Shares 19,816,913
Forward Eps -1.53
Forward P E -0.7156863
Free Cashflow -11,171,375
Full Exchange Name NasdaqCM
Full Time Employees 38
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.66972
Gross Profits 803,000
Has Pre Post Market Data 1
Held Percent Insiders 0.056799997
Held Percent Institutions 0.06152
Implied Shares Outstanding 29,281,138
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-02-12
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,711,497,600
Last Split Factor 1:10
Long Business Summary Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Long Name Longeveron Inc.
Market us_market
Market Cap 32,062,846
Market State REGULAR
Max Age 86,400
Message Board Id finmb_410711455
Most Recent Quarter 1,767,139,200
Name Change Date 2,026-04-16
Net Income To Common -22,704,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 32,209,251
Number Of Analyst Opinions 3
Open 1.1
Operating Cashflow -18,645,000
Operating Margins -14.7917795
Payout Ratio 0.0
Phone 844 470 2550
Prev Name Longeveron LLC
Previous Close 1.1
Price Hint 4
Price To Book 4.4331985
Price To Sales Trailing12 Months 26.741323
Profit Margins 0.0
Quick Ratio 1.166
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.004999995
Regular Market Change Percent -0.4524473
Regular Market Day High 1.14
Regular Market Day Low 1.0801
Regular Market Day Range 1.0801 - 1.14
Regular Market Open 1.1
Regular Market Previous Close 1.1
Regular Market Price 1.095
Regular Market Time 1,776,455,704
Regular Market Volume 866,229
Return On Assets -0.81266
Return On Equity -1.6474899
Revenue Growth -0.395
Revenue Per Share 0.068
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 27,797,133
Shares Percent Shares Out 0.082200006
Shares Short 2,406,104
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 1,530,744
Short Name Longeveron Inc.
Short Percent Of Float 0.089700006
Short Ratio 0.17
Source Interval 15
State FL
Symbol LGVN
Target High Price 10.45
Target Low Price 2.0
Target Mean Price 5.48333
Target Median Price 4.0
Total Cash 4,661,000
Total Cash Per Share 0.2
Total Debt 824,000
Total Revenue 1,199,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.29
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 0.838845
Two Hundred Day Average Change 0.256155
Two Hundred Day Average Change Percent 0.3053663
Type Disp Equity
Volume 866,229
Website https://longeveron.com
Zip 33,136